Jacob Asset Management of New York LLC Decreases Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Jacob Asset Management of New York LLC trimmed its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 15.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 277,015 shares of the biotechnology company’s stock after selling 49,642 shares during the period. Jacob Asset Management of New York LLC owned approximately 0.23% of Heron Therapeutics worth $321,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of HRTX. Sei Investments Co. purchased a new position in Heron Therapeutics in the 1st quarter worth about $27,000. Citigroup Inc. raised its holdings in shares of Heron Therapeutics by 195.6% during the second quarter. Citigroup Inc. now owns 30,845 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 20,412 shares during the last quarter. Point72 Middle East FZE bought a new position in Heron Therapeutics during the fourth quarter valued at approximately $37,000. Raymond James Financial Services Advisors Inc. purchased a new stake in Heron Therapeutics in the second quarter worth approximately $38,000. Finally, Graham Capital Management L.P. bought a new stake in Heron Therapeutics in the 1st quarter worth approximately $38,000. Institutional investors own 81.77% of the company’s stock.

Insider Transactions at Heron Therapeutics

In related news, CEO Craig A. Collard bought 150,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were bought at an average cost of $0.92 per share, for a total transaction of $138,000.00. Following the completion of the transaction, the chief executive officer now owns 186,496 shares of the company’s stock, valued at $171,576.32. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Ira Duarte purchased 85,000 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was acquired at an average cost of $0.89 per share, for a total transaction of $75,650.00. Following the completion of the transaction, the chief financial officer now directly owns 85,000 shares in the company, valued at approximately $75,650. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Craig A. Collard acquired 150,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average price of $0.92 per share, for a total transaction of $138,000.00. Following the completion of the transaction, the chief executive officer now directly owns 186,496 shares in the company, valued at $171,576.32. The disclosure for this purchase can be found here. 6.40% of the stock is currently owned by company insiders.

Heron Therapeutics Stock Up 18.9 %

HRTX traded up $0.17 during trading on Friday, hitting $1.09. The company’s stock had a trading volume of 7,782,923 shares, compared to its average volume of 2,273,640. The business’s 50 day simple moving average is $0.86 and its 200-day simple moving average is $1.26. The firm has a market cap of $163.58 million, a PE ratio of -1.14 and a beta of 1.12. Heron Therapeutics, Inc. has a one year low of $0.50 and a one year high of $3.41.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HRTX. Needham & Company LLC dropped their price target on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday. StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.